How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Integrating case counts with genomic sequences quantifies real-time transmission advantages of viral variants.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Disclaimer: Calculator results and default inputs are ...

Our tool calculates your customized insurance rates. We'll show you the average cost of our recommendation, or the cost of a policy you customize yourself. First, let’s see what the minimum coverage ...

When you sell investments for a profit, you may owe capital gains tax on the money you make. How much you pay is determined by how long you owned the asset before selling it, as well as your taxable ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...